Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
IPO Year: 2014
Exchange: NASDAQ
Website: viridiantherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $37.00 → $27.00 | Overweight → Equal Weight | Wells Fargo |
| 11/25/2024 | Buy | TD Cowen | |
| 9/11/2024 | $30.00 → $38.00 | Buy | Needham |
| 6/11/2024 | $29.00 | Outperform | Wolfe Research |
| 6/6/2024 | $23.00 | Buy | Goldman |
| 5/9/2024 | Buy → Neutral | Ladenburg Thalmann | |
| 5/9/2024 | $25.00 → $20.00 | Buy → Neutral | B. Riley Securities |
| 6/14/2023 | $51.00 | Outperform | Credit Suisse |
| 6/14/2023 | $46.00 | Buy | BTIG Research |
| 5/30/2023 | $44.00 | Outperform | RBC Capital Mkts |
- Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p < 0.0001) - - THRIVE-2 is the first global phase 3 study in patients with chronic TED to demonstrate a statistically significant and clinically meaningful 56% diplopia responder rate (placebo-adjusted rate of 31%, p = 0.0006) and 32% rate of diplopia complete resolution (placebo-adjusted rate of 18%, p = 0.0152) - - Veligrotug was generally well-tolerated with 94% of patients completing their treatment course and a 9.6% placebo-adjusted rate of hearing impairment - - BLA submission for veligrotug
- THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December 16, at 8:00 a.m. ET - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under "Events and Presenta
- Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder rate (PRR) of 70% and a placebo-adjusted PRR of 64% (p < 0.0001) - - All secondary endpoints were highly statistically significant (p < 0.0001), with clinically meaningful patient outcomes, including complete resolution of diplopia in 54% of patients (placebo-adjusted rate of 43%) and reduction of Clinical Activity Score (CAS) to 0 or 1 in 64% of patients (placebo-adjusted reduction of 46%) treated with veligrotug - - Veligrotug was generally well-tolerated with no treatment-r
- THRIVE global phase 3 clinical trial evaluated efficacy and safety of VRDN-001 in patients with active thyroid eye disease (TED) - - Conference call and webcast to be held Tuesday, September 10, at 8:00 a.m. ET - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, will host a conference call and webcast to report topline data for the THRIVE phase 3 clinical trial, evaluating VRDN-001 in patients with active TED, on Tuesday, September 10, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under "Events and Presentations" on the In
- THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topline readout expected in September 2024 - - THRIVE-2 VRDN-001 global phase 3 clinical trial for patients with chronic TED remains on track for topline readout by year-end 2024 - - Positive VRDN-003 Type C meeting held with the US Food and Drug Administration (FDA); pivotal program on track to start mid-year 2024 - - VRDN-006 FcRn inhibitor remains on track for Investigational New Drug (IND) submission by year-end 2024; non-human primate data expected for VRDN-008, a half-life extended FcRn inhibitor, in the second half of 2024 - - Con
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, May 8 at 8:00 a.m. ET to discuss its first quarter 2024 financial results and recent business highlights. The webcast can be accessed under "Events and Presentations" on the Investors section of the Viridian website at viridiantherapeutics.com. To participate in the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference code 7373356. A replay of the webcast will be available following the completion of the
- VRDN-003 clinical data exceeded expectations with extended half-life of 40-50 days, 4-5x longer than VRDN-001, supporting a potential best-in-class, low-volume, less frequent, self-administered subcutaneous therapy for thyroid eye disease (TED) - - Data support VRDN-003 dosing as infrequently as once every eight weeks and is expected to reach exposure levels associated with robust clinical response in earlier trials of VRDN-001 in TED patients - - Pivotal clinical development of subcutaneous VRDN-003 in TED patients expected to initiate mid-2024 pending alignment with regulatory authorities - - Viridian to host investor conference call and webcast today at 8:00am ET - Viridian The
- THRIVE and THRIVE-2 clinical trials are continuing to enroll active and chronic thyroid eye disease (TED) patients; expected delivery of topline clinical results for both clinical trials on track for 2024 - - Timing for the selection of lead subcutaneous TED program is on track for the end of 2023 - - Advancing recently announced novel preclinical portfolio of potentially best-in-class neonatal Fc receptor (FcRn) inhibitors with the broad potential to treat autoimmune diseases - - Announced the appointment of Stephen Mahoney as President and Chief Executive Officer - - Closed a private placement of approximately $185 million with new and existing investors to fund pipeline develop
- Reported positive topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) - - THRIVE Phase 3 trial in patients with active TED amended to reflect Viridian's confidence in 5-infusion treatment regimen and key stakeholder feedback on evolving TED treatment paradigm – - THRIVE-2 Phase 3 trial in patients with chronic TED expected to start in the third quarter of 2023 – - Selection of lead subcutaneous (SC) program in TED planned for year-end 2023 - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced finan
- VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg – - Ongoing THRIVE Phase 3 trial in patients with active TED amended to reflect Viridian's confidence in 5-dose regimen and key stakeholder feedback on evolving TED treatment paradigm - - THRIVE-2 Phase 3 trial in patients with chronic TED expected to start in third quarter 2023 – - 3 mg/kg data support low-volume subcutaneous (SC) dosing profile for Company's SC candidates in TED - - Viridian plans to select lead SC program candidate by year-end 2023; VRDN-001 SC IND amendment and VRDN-003 IND submitted
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13D/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13D/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
SC 13G/A - Viridian Therapeutics, Inc.\DE (0001590750) (Subject)
8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
10-Q - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
424B5 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
424B5 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
S-8 - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
8-K - Viridian Therapeutics, Inc.\DE (0001590750) (Filer)
Viridian Therapeutics, Inc. (NASDAQ:VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jennifer Tousignant to the role of Chief Legal Officer. "I am very pleased to welcome Jennifer to Viridian to lead our legal team and join Viridian's executive team ahead of an exciting set of milestones this year across our thyroid eye disease and anti-neonatal Fc receptor portfolios," said Steve Mahoney, Viridian President and Chief Executive Officer. "With Jennifer's deep expertise and long history in public biotech companies advising on a broad set o
– Stephen Mahoney appointed President and Chief Executive Officer – – Potential best-in-class subcutaneous and intravenous thyroid eye disease (TED) programs targeting insulin-like growth factor 1 receptor (IGF-1R) remain on track; subcutaneous program selection expected by year-end 2023 and VRDN-001 THRIVE Phase 3 topline results in active TED expected in mid-2024 – – Company discloses novel portfolio of preclinical neonatal Fc receptor (FcRn) inhibitors with broad potential to treat autoimmune diseases; first Investigational New Drug (IND) submission planned by year end 2024 – – Private placement with participation from new and existing investors to fund portfolio strategy and exten
WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Tony Casciano to the role of Chief Commercial Officer (CCO). The Company also announced that Chief Operating Officer (COO) Carrie Melvin is no longer with the organization. Mr. Casciano, who most recently served as Chief Executive Officer (CEO) and member of the board of directors of Teal Bio, brings to Viridian more than two decades of sales, marketing, and commercial leadership experience in the biopharma industry. "Tony's arr
WALTHAM, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that the Company has appointed Scott Myers as President and Chief Executive Officer, and a member of the Board of Directors, effective today February 6, 2023. Mr. Myers has more than 30 years of biopharmaceutical and medical technology experience, and has held global executive leadership and director roles at numerous commercial- and development-stage biopharmaceutical companies. He succeeds Jonathan Violin, Ph.D. who has led Viridian since its inception
WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company. "As we prepare for late-stage clinical development for our TED programs, we are excited to add Carrie to the Viridian team" said Jonathan Violin, Ph.D., Viridian Therapeutics' President and CEO. "Carrie's extensive experience in a wide range of operational activities supporting product development and approval will be tremendously valuable to our expanding
BOULDER, Colo., July 26, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced the appointment of Kristian Humer as its new Chief Financial Officer and Chief Business Officer. "Kristian brings extensive global finance experience as our new CFO and CBO. His appointment builds upon the tremendously talented team of executives we've already assembled in recent months, as we advance our pipeline of investigational therapies to address serious diseases with significant unmet medical needs," commented Jonathan Violin, Ph.D., Presid
BOULDER, Colo., July 15, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced the appointment of Jennifer Moses, CPA to the Company's Board of Directors and as Chair of the Audit Committee. "We are excited to welcome Jennifer to our Board of Directors and as Chair of the Audit Committee. She provides strong financial and strategic experience as a successful leader in the biotechnology industry. Her addition to the Board and as Chair of the Audit Committee will be of great benefit to Viridian as we rapidly advance the clinica
Progressed lead programs VRDN-001 and VRDN-002 towards clinical trials in Thyroid Eye Disease (TED); both IND filings expected by the end of 2021 Completed integration and name change to Viridian Therapeutics following October 2020 merger and concurrent financing Ended 2020 with a strong cash position of $127.6 million, and runway into the second half of 2023Strengthened leadership team with the appointment of Dr. Jonathan Violin as CEO and additions of Dr. Barrett Katz as CMO and Dr. Vahe Bedian as Chief Scientist BOULDER, Colo., March 25, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
3 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
- Veligrotug, with recent positive phase 3 topline data in both active and chronic thyroid eye disease (TED), has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with less drug and fewer infusions; Biologics License Application (BLA) submission on track for second half of 2025 - - REVEAL-1 and REVEAL-2, phase 3 clinical trials for subcutaneous (SC) VRDN-003 in active and chronic TED respectively, are currently dosing patients; topline data for both trials, which are evaluating VRDN-003 dosed Q4W or Q8W, is on track for the first half of 2026 - - Investigational New Drug (IND) submitted in December 2024 for VRDN-006, an Fc fragment i
- Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p < 0.0001) - - THRIVE-2 is the first global phase 3 study in patients with chronic TED to demonstrate a statistically significant and clinically meaningful 56% diplopia responder rate (placebo-adjusted rate of 31%, p = 0.0006) and 32% rate of diplopia complete resolution (placebo-adjusted rate of 18%, p = 0.0152) - - Veligrotug was generally well-tolerated with 94% of patients completing their treatment course and a 9.6% placebo-adjusted rate of hearing impairment - - BLA submission for veligrotug
- THRIVE-2 global phase 3 clinical trial evaluated efficacy and safety of veligrotug in patients with chronic thyroid eye disease (TED) - - Conference call and webcast to be held Monday, December 16, at 8:00 a.m. ET - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced plans to host a conference call and webcast to report topline data for the THRIVE-2 phase 3 clinical trial, evaluating veligrotug in chronic TED, on Monday, December 16, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under "Events and Presenta
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 391,500 shares of the company's common stock to 10 new employees (the "Inducement Grants") on December 2, 2024 (the "Grant Date"). The Inducement Grants have been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the "Plan") but remain subject to the terms and conditions of such
- Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in December 2024 - - Initiated two global phase 3 clinical trials of subcutaneous VRDN-003, REVEAL-1 and REVEAL-2 in August, in active and chronic TED, respectively; topline data anticipated in the first half of 2026 - - New non-human primate (NHP) data for VRDN-008, a next-generation bispecific neonatal Fc receptor (FcRn) inhibitor, demonstrates a potential best-in-class pharmacokinetic (PK) and pharmacodynamic (PD) profile; Investigational New Drug (IND) submission is planned for year-end 2025 and proof
Viridian Therapeutics, Inc. (NASDAQ:VRDN) (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 150,600 shares of the company's common stock to six new employees (the "Inducement Grants") on November 1, 2024 (the "Grant Date"). The Inducement Grants have been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the "Plan") but remain subject to th
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the pricing of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, shares of Series B non-voting convertible preferred stock. Viridian is selling a total of 10,666,600 shares of common stock at a public offering price of $18.75 per share and 20,000 shares of Series B non-voting convertible preferred stock at a public offering price of $1,250.06250 per share, which are convertible into 1,333,400 shares of common stock, subject to beneficial ownershi
Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock and Series B non-voting convertible preferred stock. All of the securities to be sold in the underwritten public offering are being offered by Viridian. In addition, Viridian intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock. Each share of Series B preferred stock will be convertible into 66.67 shares of common stock at the election of
- Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder rate (PRR) of 70% and a placebo-adjusted PRR of 64% (p < 0.0001) - - All secondary endpoints were highly statistically significant (p < 0.0001), with clinically meaningful patient outcomes, including complete resolution of diplopia in 54% of patients (placebo-adjusted rate of 43%) and reduction of Clinical Activity Score (CAS) to 0 or 1 in 64% of patients (placebo-adjusted reduction of 46%) treated with veligrotug - - Veligrotug was generally well-tolerated with no treatment-r
- THRIVE global phase 3 clinical trial evaluated efficacy and safety of VRDN-001 in patients with active thyroid eye disease (TED) - - Conference call and webcast to be held Tuesday, September 10, at 8:00 a.m. ET - Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, will host a conference call and webcast to report topline data for the THRIVE phase 3 clinical trial, evaluating VRDN-001 in patients with active TED, on Tuesday, September 10, 2024 at 8:00am ET. Conference call and webcast information The webcast can be accessed under "Events and Presentations" on the In
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
4 - Viridian Therapeutics, Inc.\DE (0001590750) (Issuer)
Wells Fargo downgraded Viridian Therapeutics from Overweight to Equal Weight and set a new price target of $27.00 from $37.00 previously
TD Cowen initiated coverage of Viridian Therapeutics with a rating of Buy
Needham reiterated coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $38.00 from $30.00 previously
Wolfe Research initiated coverage of Viridian Therapeutics with a rating of Outperform and set a new price target of $29.00
Goldman initiated coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $23.00
Ladenburg Thalmann downgraded Viridian Therapeutics from Buy to Neutral
B. Riley Securities downgraded Viridian Therapeutics from Buy to Neutral and set a new price target of $20.00 from $25.00 previously
Credit Suisse resumed coverage of Viridian Therapeutics with a rating of Outperform and set a new price target of $51.00
BTIG Research initiated coverage of Viridian Therapeutics with a rating of Buy and set a new price target of $46.00
RBC Capital Mkts initiated coverage of Viridian Therapeutics with a rating of Outperform and set a new price target of $44.00